TABLE 1.

Clinical data for mpox cases

Patient	CD4+ T-cell count (cells/mm3)a	HIV viral load (copies/mL)a	Mpox treatment and Specimen Collection History	Clinical outcome
A	<35	130,565	Tecovirimat POc 600 mg: BIDd, 1 wk Tecovirimat PO 600 mg: BID, 1 wk Tecovirimat IVe 200 mg: 3 doses Tecovirimat PO 600 mg: BID, 2 wks Tecovirimat IV 200 mg: qf 12 hours, 2 days Specimen A.1 collected VIGIVg (unknown dose): single infusion Tecovirimat IV 200 mg: q 12 hours, 2 wks Specimens A.2-A.26 collected	Deceased
B	73	<20	Tecovirimat PO 600 mg: BID, 2 wks Tecovirimat PO 600 mg: BID, 2 wks Specimens B.1-B.2 collected Tecovirimat IV 200 mg: q 12 hours, 2 wks VIGIV (unknown dose): single infusion Brincidofovir PO (unknown dose): single dose	Unknown
C	136	178,982	Tecovirimat PO 200-600 mg: QDh-BID, 2 wks Tecovirimat IV 200 mg: q 12 hours, 3 wks Specimens C.1-C.2 collected VIGIV (unknown dose): single infusion	Ongoing lesions (after 6 mo)
D	96	2,620	Tecovirimat PO 600 mg: BID, 2 wks Tecovirimat PO 600 mg: BID, 11 days Specimen D.1 collectedb Cidofovir IV 5 mg/kg: single infusion Tecovirimat PO 600 mg: BID, 4 days VIGIV 9000 units/kg: single infusion Tecovirimat IV 200 mg: q 12 hours, 2 wks Cidofovir IV 5 mg/kg: single infusion	Recovered
E	191	606	Tecovirimat PO 600 mg: BID, 2 wks Tecovirimat PO 600 mg: BID, 4 wks Specimens E.1-E.8 collected Tecovirimat PO 600 mg: BID, 6 wks Tecovirimat PO 600 mg: BID, 10 wks Specimens E.9-E.14 collected	Ongoing lesions (after 6 mo)
F	54	485,298	Specimen F.1 collected Tecovirimat PO 600 mg: BID, 1 wk Tecovirimat PO 600 mg: BID, 2 days Tecovirimat IV 200 mg: q 12 hours, 4 days Specimens F.2-F.5 collected	Ongoing lesions (after 7 mo)

^aResults are most proximal to case identification and management. Specimen collection history is in bold text.

^bSpecimen D.1 was collected 5 days into preceding tecovirimat treatment course.

^cPO = Per Oral.

^dBID = Twice daily.

^eIV = Intravenous.

^fq = every.

^gVIGIV = Vaccinia Immune Globulin Intravenous.

^hQD = Once daily.